PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerviewpress.com

subscribe
share





Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes


Go online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring systems, and their potential impacts on clinical decision-making, Explain the current therapeutic role of JAK inhibitors and emerging novel combination therapies in the management of myelofibrosis, Review the latest clinical evidence supporting the use of first- and second-generation JAK inhibitors and other investigational JAK inhibitor-based combinations in the management of myelofibrosis, Develop individualized, safe, risk-adapted treatment protocols for patients with symptomatic or asymptomatic myelofibrosis, including those with high-risk mutations or who fail prior JAK inhibitor therapy.


share







 2021-09-11  37m